E
Erwin H. Fleischmann
Researcher at University of Erlangen-Nuremberg
Publications - 13
Citations - 438
Erwin H. Fleischmann is an academic researcher from University of Erlangen-Nuremberg. The author has contributed to research in topics: Renal function & Angiotensin II. The author has an hindex of 10, co-authored 13 publications receiving 429 citations.
Papers
More filters
Journal ArticleDOI
Additional Antiproteinuric Effect of Ultrahigh Dose Candesartan: A Double-Blind, Randomized, Prospective Study
Roland E. Schmieder,Arnfried U. Klingbeil,Erwin H. Fleischmann,Roland Veelken,Christian Delles +4 more
TL;DR: The data indicate an additive antiproteinuric effect of ultrahigh dose of the angiotensin receptor blocker candesartan compared with standard dose.
Journal ArticleDOI
Rapid nongenomic effects of aldosterone on human forearm vasculature.
Bernhard Schmidt,Sebastian Oehmer,Christian Delles,Renate Bratke,Markus P. Schneider,Arnfried U. Klingbeil,Erwin H. Fleischmann,Roland E. Schmieder +7 more
TL;DR: The data suggest that aldosterone acts through rapid nongenomic effects at the endothelium by increasing NO release and at the vascular smooth muscle cells by promoting vasoconstriction, consistent with in vitro data showing an increase in intracellular calcium in both cell types.
Journal ArticleDOI
Are all antihypertensive drug classes equal in reducing left ventricular hypertrophy
TL;DR: The most recently published Losartan Intervention For Endpoint reduction in hypertension study confirmed the superiority of angiotensin receptor blockers against β-blockers in a large-scale prospective trial and proves for the first time that regression of LVH is associated with better cardiovascular outcome.
Journal ArticleDOI
Impaired basal NO activity in patients with glomerular disease and the influence of oxidative stress
Tim Schäufele,Markus P. Schlaich,Christian Delles,Arnfried U. Klingbeil,Erwin H. Fleischmann,Roland E. Schmieder +5 more
TL;DR: It is suggested that basal NO activity of the renal vasculature is reduced in patients with chronic glomerular disease compared to age- and blood pressure-matched control subjects, in part related to increased oxidative stress.
Journal ArticleDOI
Active immunization against hepatitis A in dialysis patients
TL;DR: It is shown that hepatitis A vaccination of dialysis patients is feasible, well tolerated and immunogenic and that the vaccine can be given subcutaneously in those patients where intramuscular administration is contra-indicated.